4D Molecular Therapeutics FDMT Deferred Revenue — Deferred Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's deferred revenue — deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is 4D Molecular Therapeutics's deferred revenue — deferred revenue?
- 4D Molecular Therapeutics (FDMT) reported deferred revenue — deferred revenue of $2.49M in Q1 2026.
- What does deferred revenue — deferred revenue mean?
- This metric represents the portion of consideration received from customers for which the company has not yet satisfied its performance obligations under gene therapy development or collaboration agreements. It reflects future revenue that will be recognized as the company fulfills its contractual milestones or service delivery requirements. Monitoring this balance provides insight into the timing of revenue recognition and the progress of long-term research and development partnerships.